MedTrace Logo

A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia

NCT00002154 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who have mild to moderate dementia (a decline in their mental abilities).

Conditions

  • Cognitive Disorders
  • HIV Infections

Interventions

DRUG

Thioctic acid

DRUG

Selegiline hydrochloride

Sponsors & Collaborators

  • The Dana Foundation

    lead OTHER

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002154 on ClinicalTrials.gov